Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infigratinib in Advanced or Metastatic Solid Tumors With FGFR Alterations
NCT04233567Phase 2Completed
- Start
- Jan 2020
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of infigratinib in solid tumor, cholangiocarcinoma (CCA). Started Jan 2020; status: completed.
02
Drugs
infigratinib
03
Conditions
solid tumorcholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT04233567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04233567.